# iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

> **NCT03350126** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Cancer Colorectal

## Interventions

- **DRUG:** Ipilimumab 200 MG in 40 ML Injection
- **DRUG:** Nivolumab 10 MG/ML

## Key facts

- **NCT ID:** NCT03350126
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-04
- **Primary completion:** 2020-01-10
- **Final completion:** 2025-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03350126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03350126, "iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03350126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*